Expression of Urotensin II and Its Receptor in Human Liver Cirrhosis and Fulminant Hepatic Failure

[1]  H. Krum,et al.  Increased circulating urotensin II in cirrhosis: Potential implications in liver disease , 2008, Peptides.

[2]  H. Krum,et al.  Urotensin II in chronic liver disease: In vivo effect on vascular tone , 2008, Scandinavian journal of gastroenterology.

[3]  F. Lammert,et al.  Hemodynamic effects of urotensin II and its specific receptor antagonist palosuran in cirrhotic rats , 2007, Hepatology.

[4]  H. Krum,et al.  Urotensin II: a novel vasoactive mediator linked to chronic liver disease and portal hypertension , 2007, Liver international : official journal of the International Association for the Study of the Liver.

[5]  P. Pacaud,et al.  Urotensin II is a New Chemotactic Factor for UT Receptor-Expressing Monocytes1 , 2007, The Journal of Immunology.

[6]  Z. Ao,et al.  Urotensin II and renal function in the rat. , 2006, Kidney international.

[7]  A. Davenport,et al.  Regional heterogeneity in the haemodynamic responses to urotensin II infusion in relation to UT receptor localisation , 2006, British journal of pharmacology.

[8]  N. Ashton,et al.  Urotensin II: Ancient Hormone with New Functions in Vertebrate Body Fluid Regulation , 2005, Annals of the New York Academy of Sciences.

[9]  N. Aiyar,et al.  Urotensin-II-mediated cardiomyocyte hypertrophy: effect of receptor antagonism and role of inflammatory mediators , 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.

[10]  Werner Müller,et al.  Interleukin 6/gp130‐dependent pathways are protective during chronic liver diseases , 2003, Hepatology.

[11]  T. Yoshimoto,et al.  Urotensin II is an autocrine/paracrine growth factor for the porcine renal epithelial cell line, LLCPK1. , 2003, Endocrinology.

[12]  O. Nayler,et al.  The Expression of Urotensin II Receptor (U2R) is Up‐regulated by Interferon‐γ , 2003, Journal of receptor and signal transduction research.

[13]  T. Dschietzig,et al.  Plasma levels and cardiovascular gene expression of urotensin-II in human heart failure , 2002, Regulatory Peptides.

[14]  C. Trautwein,et al.  Imbalanced intrahepatic expression of interleukin 12, interferon gamma, and interleukin 10 in fulminant hepatitis B , 2002, Hepatology.

[15]  T. Sauerbruch,et al.  Increased urotensin II plasma levels in patients with cirrhosis and portal hypertension. , 2001, Journal of hepatology.

[16]  A. Davenport,et al.  Depressor and regionally‐selective vasodilator effects of human and rat urotensin II in conscious rats , 2001, British journal of pharmacology.

[17]  S. Douglas,et al.  Potent vasodilator responses to human urotensin-II in human pulmonary and abdominal resistance arteries. , 2001, American journal of physiology. Heart and circulatory physiology.

[18]  H. Sarau,et al.  Differential vasoconstrictor activity of human urotensin‐II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey , 2000, British journal of pharmacology.

[19]  N. Aiyar,et al.  Human urotensin-II is a potent vasoactive peptide: pharmacological characterization in the rat, mouse, dog and primate. , 2000, Journal of cardiovascular pharmacology.

[20]  Roger Williams,et al.  The systemic inflammatory response syndrome in acute liver failure , 2000, Hepatology.

[21]  S. Douglas,et al.  Human urotensin‐II is an endothelium‐dependent vasodilator in rat small arteries , 2000, British journal of pharmacology.

[22]  H. Sarau,et al.  Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14 , 1999, Nature.

[23]  M. Manns,et al.  Enhanced expression of CD80 (B7-1), CD86 (B7-2), and CD40 and their ligands CD28 and CD154 in fulminant hepatic failure. , 1999, The American journal of pathology.

[24]  R. Persaud,et al.  Statistics: the glitter of the t table , 1993, The Lancet.

[25]  Roger Williams,et al.  Acute liver failure: redefining the syndromes , 1993, The Lancet.